المؤلفون: A. L. Kurenkov, B. I. Bursagova, A. R. Artemenko, А. Л. Куренков, Б. И. Бурсагова, А. Р. Артеменко

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 1 (2024); 94-101 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 1 (2024); 94-101 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-1

مصطلحات موضوعية: которая обусловлена спастичностью», pain, associated with spasticity, botulinum therapy, incobotulinumtoxin A, lower limb spasticity, upper limb spasticity, efficacy, Questionnaire on Pain caused by Spasticity, боль, связанная со спастичностью, ботулинотерапия, инкоботулотоксин А, спастичность нижних конечностей, спастичность верхних конечностей, эффективность, опросник «Анкета боли

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/2189/1635Test; Bax M, Goldstein M, Rosenbaum P, et al; Executive Committee for the Definition of Cerebral Palsy. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005 Aug;47(8):571-6. doi:10.1017/s001216220500112x; Graham HK, Rosenbaum P, Paneth N, et al. Cerebral palsy. Nat Rev Dis Primers. 2016 Jan 7;2:15082. doi:10.1038/nrdp.2015.82; Ostojic K, Paget SP, Morrow AM. Management of pain in children and adolescents with cerebral palsy: a systematic review. Dev Med Child Neurol. 2019 Mar;61(3):315-21. doi:10.1111/dmcn.14088. Epub 2018 Oct 31.; Badia M, Riquelme I, Orgaz B, et al. Pain, motor function and health-related quality of life in children with cerebral palsy as reported by their physiotherapists. BMC Pediatr. 2014 Jul 27;14:192. doi:10.1186/1471-2431-14-192; McCormick A. Quality of life. In: Panteliadis CP, ed. Cerebral palsy: Multidisciplinary approach. 3rd ed. Cham: Springer; 2018. P.335-42.; Mckinnon CT, Meehan EM, Harvey AR, et al. Prevalence and characteristics of pain in children and young adults with cerebral palsy: a systematic review. Dev Med Child Neurol. 2019 Mar;61(3):305-14. doi:10.1111/dmcn.14111. Epub 2018 Dec 3.; Penner M, Xie WY, Binepal N, et al. Characteristics of pain in children and youth with cerebral palsy. Pediatrics. 2013 Aug;132(2):e407-13. doi:10.1542/peds.2013-0224. Epub 2013 Jul 15.; Eriksson E, Hägglund G, Alriksson-Schmidt AI. Pain in children and adolescents with cerebral palsy – a crosssectional register study of 3545 individuals. BMC Neurol. 2020 Jan 11;20(1):15. doi:10.1186/s12883-019-1597-7; Ostergaard CS, Pedersen NSA, Thomasen A, et al. Pain is frequent in children with cerebral palsy and negatively affects physical activity and participation. Acta Paediatr. 2021 Jan;110(1):301-6. doi:10.1111/apa.15341. Epub 2020 May 26.; Sultan T, Wong C. Presence and grade of undertreatment of pain in children with cerebral palsy. Scand J Pain. 2023 Jun 2;23(3):546-52. doi:10.1515/sjpain-2022-0124; Parkinson KN, Dickinson HO, Arnaud C, et al; SPARCLE group. Pain in young people aged 13 to 17 years with cerebral palsy: crosssectional, multicentre European study. Arch Dis Child. 2013 Jun;98(6):434-40. doi:10.1136/archdischild-2012-303482. Epub 2013 Apr 20.; Westbom L, Rimstedt A, Nordmark E. Assessments of pain in children and adolescents with cerebral palsy: a retrospective populationbased registry study. Dev Med Child Neurol. 2017 Aug;59(8):858-63. doi:10.1111/dmcn.13459. Epub 2017 May 16.; Ostojic K, Paget S, Kyriagis M, Morrow A. Acute and Chronic Pain in Children and Adolescents With Cerebral Palsy: Prevalence, Interference, and Management. Arch Phys Med Rehabil. 2020 Feb;101(2):213-9. doi:10.1016/j.apmr.2019.08.475. Epub 2019 Sep 12.; Hareb F, Bertoncelli CM, Rosello O, et al. Botulinum Toxin in Children with Cerebral Palsy: An Update. Neuropediatrics. 2020 Feb;51(1):1-5. doi:10.1055/s-0039-1694988. Epub 2019 Sep 4.; Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep. 2020 Feb 21;20(2):3. doi:10.1007/s11910-020-1022-z; Heinen F, Kanovsky P, Schroeder AS, et al. IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study. J Pediatr Rehabil Med. 2021;14(2):183-97. doi:10.3233/PRM-210040. Erratum in: J Pediatr Rehabil Med. 2022;15(2):407-9.; Tilton A, Russman B, Aydin R, et al. AbobotulinumtoxinA (Dysport®) Improves Function According to Goal Attainment in Children With Dynamic Equinus Due to Cerebral Palsy. J Child Neurol. 2017 Apr;32(5):482-7. doi:10.1177/0883073816686910. Epub 2017 Jan 9.; Kanovsky P, Heinen F, Schroeder AS, et al. Safety and efficacy of repeat long-term incobotulinumtoxinA treatment for lower limb or combined upper/lower limb spasticity in children with cerebral palsy. J Pediatr Rehabil Med. 2022;15(1):113-27. doi:10.3233/PRM210041; Roscigno CI. Addressing spasticity-related pain in children with spastic cerebral palsy. J Neurosci Nurs. 2002 Jun;34(3):123-33. doi:10.1097/01376517-200206000-00005; Almina S, Karile Y, Audrone P, Indre B. Analgesic effect of botulinum toxin in children with cerebral palsy: A systematic review. Toxicon. 2021 Aug;199:60-7. doi:10.1016/j.toxicon.2021.05.012. Epub 2021 Jun 1.; Sandahl Michelsen J, Normann G, Wong C. Analgesic Effects of Botulinum Toxin in Children with CP. Toxins (Basel). 2018 Apr 19;10(4):162. doi:10.3390/toxins10040162; Dabrowski E, Chambers HG, Gaebler-Spira D, et al. Incobotulinumtoxin A Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial. Pediatr Neurol. 2021 Oct;123:10-20. doi:10.1016/j.pediatrneurol.2021.05.014. Epub 2021 May 21.; Geister TL, Quintanar-Solares M, Martin M, et al. Qualitative development of the 'Questionnaire on Pain caused by Spasticity (QPS),' a pediatric patient-reported outcome for spasticity-related pain in cerebral palsy. Qual Life Res. 2014 Apr;23(3):887-96. doi:10.1007/s11136-013-0526-2. Epub 2013 Sep 24.; Geister TL, Bushnell DM, Yang J, et al. Initial psychometric validation of the questionnaire on pain caused by spasticity (QPS). Health Qual Life Outcomes. 2017 Nov 28;15(1):229. doi:10.1186/s12955-017-0804-8; Heinen F, Bonfert M, Kanovsky P, et al. Spasticity-related pain in children/adolescents with cerebral palsy. Part 1: Prevalence and clinical characteristics from a pooled analysis. J Pediatr Rehabil Med. 2022;15(1):129-43. doi:10.3233/PRM-220011; Bonfert M, Heinen F, Kanovsky P, et al. Spasticity-related pain in children/adolescents with cerebral palsy. Part 2: IncobotulinumtoxinA efficacy results from a pooled analysis. J Pediatr Rehabil Med. 2023;16(1):83-98. doi:10.3233/PRM-220020; https://nnp.ima-press.net/nnp/article/view/2189Test

الإتاحة: https://doi.org/10.14412/2074-2711-2024-1-94-101Test
https://doi.org/10.14412/2074-2711-2024-1Test
https://doi.org/10.1017/s001216220500112xTest
https://doi.org/10.1038/nrdp.2015.82Test
https://doi.org/10.1111/dmcn.14088Test
https://doi.org/10.1186/1471-2431-14-192Test
https://doi.org/10.1111/dmcn.14111Test
https://doi.org/10.1542/peds.2013-0224Test
https://doi.org/10.1186/s12883-019-1597-7Test
https://doi.org/10.1111/apa.15341Test

المؤلفون: V. A. Tolmacheva, D. S. Petelin, B. A. Volel, В. А. Толмачева, Д. С. Петелин, Б. А. Волель

المساهمون: The investigation has not been sponsored, Исследование не имело спонсорской поддержки

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 5 (2023); 35-38 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 5 (2023); 35-38 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-5

مصطلحات موضوعية: качество жизни, botulinum therapy, quality of life, ботулинотерапия

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/2102/1582Test; Defazio G, Jankovic J, Giel JL, Papapetropoulos S. Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013 Nov 4;3:tre-03-193-4374-2. doi:10.7916/D80C4TGJ; Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007 Oct;13(7):4116. doi:10.1016/j.parkreldis.2007.02.005. Epub 2007 Apr 17.; Hok P, Veverka T, Hlustik P, et al. The Central Effects of Botulinum Toxin in Dystonia and Spasticity. Toxins (Basel). 2021 Feb 17;13(2):155. doi:10.3390/toxins13020155; Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013 Jun 15;28(7):863-73. doi:10.1002/mds.25475. Epub 2013 May 6.; Jog M, Chouinard S, Hobson D, et al. Causes for treatment delays in dystonia and hemifacial spasm: a Canadian survey. Can J Neurol Sci. 2011 Sep;38(5):704-11. doi:10.1017/s0317167100012270; Abdo WF, van de Warrenburg BP, Burn DJ, et al. The clinical approach to movement disorders. Nat Rev Neurol. 2010 Jan;6(1):29-37. doi:10.1038/nrneurol.2009.196; Neeraja K, Prasad S, Surisetti BK, et al. Cervical Myeloradiculopathy and Atlantoaxial Instability in Cervical Dystonia. World Neurosurg. 2021 Feb;146:e1287-e1292. doi:10.1016/j.wneu.2020.11.153. Epub 2020 Dec 4.; Vergallo A, Cocco A, De Santis T, et al. Eligibility criteria in clinical trials for cervical dystonia. Parkinsonism Relat Disord. 2022 Nov;104:110-4. doi:10.1016/j.parkreldis.2022.10.003. Epub 2022 Oct 7.; Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007 Sep 8;370(9590):851-8. doi:10.1016/S0140-6736(07)61415-9; Liu X, Cao H, Zhu H, et al. Association of chronic diseases with depression, anxiety and stress in Chinese general population: The CHCN-BTH cohort study. J Affect Disord. 2021 Mar 1;282:1278-87. doi:10.1016/j.jad.2021.01.040. Epub 2021 Jan 14.; Салоухина НИ, Нодель МР, Толмачева ВА. Недвигательные нарушения у пациентов с мышечной дистонией. Журнал неврологии и психиатрии им. C.C. Корсакова. 2018;118(9):98-105. doi:10.17116/jnevro201811809198; Medina Escobar A, Martino D, Goodarzi Z. The prevalence of anxiety in adult-onset isolated dystonia: A systematic review and meta-analysis. Eur J Neurol. 2021 Dec;28(12):4238-50. doi:10.1111/ene.15050. Epub 2021 Aug 16.; Нодель МР, Салоухина НИ, Толмачева ВА. Влияние недвигательных расстройств на качество жизни пациентов с цервикальной мышечной дистонией. Неврология, нейропсихиатрия, психосоматика. 2022;14(3):19-25. doi:10.14412/20742711-2022-3-19-25; Толмачева ВА, Юзбашян ПГ, Петелин ДС и др. Расстройства тревожнодепрессивного спектра при цервикальной дистонии. Неврология, нейропсихиатрия, психосоматика. 2022;14(4):38-43. doi:10.14412/2074-2711-2022-4-38-43; Дружинина ОА, Жукова НГ, Шперлинг ЛП, Новотный ДA. Цервикальная дистония: немоторные аспекты. Неврология, нейропсихиатрия, психосоматика. 2020;12(3):69-74.; Colosimo C, Tiple D, Berardelli A. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res. 2012 Nov;22(4):265-73. doi:10.1007/s12640-012-9314-y. Epub 2012 Feb 23.; Colosimo C, Charles D, Misra VP, et al; INTEREST IN CD2 study group. Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study. J Neurol Sci. 2020 Sep 15;416:117015. doi:10.1016/j.jns.2020.117015. Epub 2020 Jul 9.; Tomic S, Petkovic I, Pucic T, et al. Cervical dystonia and quality of life. Acta Neurol Belg. 2016 Dec;116(4):589-92. doi:10.1007/s13760016-0634-1. Epub 2016 May 2.; Novaretti N, Cunha ALN, Bezerra TC, et al. The Prevalence and Correlation of Non-motor Symptoms in Adult Patients with Idiopathic Focal or Segmental Dystonia. Tremor Other Hyperkinet Mov (N Y). 2019 Feb 4;9:596. doi:10.7916/fhnv-v355; Rodrigues FB, Duarte GS, Marques RE, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2020 Nov 12;11(11):CD003633. doi:10.1002/14651858.CD003633.pub4; https://nnp.ima-press.net/nnp/article/view/2102Test

الإتاحة: https://doi.org/10.14412/2074-27112023-5-35-38Test
https://doi.org/10.14412/2074-2711-2023-5Test
https://doi.org/10.7916/D80C4TGJTest
https://doi.org/10.1016/j.parkreldis.2007.02.005Test
https://doi.org/10.3390/toxins13020155Test
https://doi.org/10.1002/mds.25475Test
https://doi.org/10.1017/s0317167100012270Test
https://doi.org/10.1038/nrneurol.2009.196Test
https://doi.org/10.1016/j.wneu.2020.11.153Test
https://doi.org/10.1016/j.parkreldis.2022.10.003Test

المؤلفون: V. A. Tolmacheva, D. V. Romanov, В. А. Толмачева, Д. В. Романов

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2023); 163–167 ; Медицинский Совет; № 10 (2023); 163–167 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: EQ-5D, blepharospasm, botulinum therapy, quality of life, disability index, BSDI, блефароспазм, ботулинотерапия, качество жизни, индекс нетрудоспособности

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7653/6786Test; Jinnah H.A. The Dystonias. Continuum (Minneap Minn). 2019;25(4):976–1000. https://doi.org/10.1212/con.0000000000000747Test.; Berardelli A., Rothwell J.C., Day B.L., Marsden C.D. Pathophysiology of blepharospasm and oromandibular dystonia. Brain. 1985;108(Pt 3): 593–608. https://doi.org/10.1093/brain/108.3.593Test.; Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double- blind crossover study. Ann Neurol. 1982;11(1):41–47. https://doi.org/10.1002/ana.410110108Test.; Grandas F., Elston J., Quinn N., Marsden C.D. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988;51(6):767–772. https://doi.org/10.1136/jnnp.51.6.767Test.; Tolosa E., Martí M.J. Blepharospasm- oromandibular dystonia syndrome (Meige’s syndrome): clinical aspects. Adv Neurol. 1988;49:73–84. Available at: https://pubmed.ncbi.nlm.nih.gov/3278555Test/.; Zoons E., Dijkgraaf M.G., Dijk J.M., van Schaik I.N., Tijssen M.A. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco- therapeutic and pharmaco- economic value. J Neurol. 2012;259(12):2519–2526. https://doi.org/10.1007/s00415-012-6510-xTest.; Jankovic J., Havins W.E., Wilkins R.B. Blinking and blepharospasm. Mechanism, diagnosis, and management. JAMA. 1982;248(23):3160–3164. https://doi.org/10.1001/jama.1982.03330230060037Test.; Tucha O., Naumann M., Berg D., Alders G.L., Lange K.W. Quality of life in patients with blepharospasm. Acta Neurol Scand. 2001;103(1):49–52. https://doi.org/10.1034/j.1600-0404.2001.00109.xTest.; Logroscino G., Livrea P., Anaclerio D., Aniello M.S., Benedetto G., Cazzato G. et al. Agreement among neurologists on the clinical diagnosis of dystonia at different body sites. J Neurol Neurosurg Psychiatry. 2003;74(3):348–350. https://doi.org/10.1136/jnnp.74.3.348Test.; Albanese A., Bhatia K., Bressman S.B., Delong M.R., Fahn S., Fung V.S. et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863–873. https://doi.org/10.1002/mds.25475Test.; Albanese A., Sorbo F.D., Comella C., Jinnah H.A., Mink J.W., Post B. et al. Dystonia rating scales: critique and recommendations. Mov Disord. 2013;28(7):874–883. https://doi.org/10.1002/mds.25579Test.; Feng Y.S., Kohlmann T., Janssen M.F., Buchholz I. Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res. 2021;30(3):647–673. https://doi.org/10.1007/s11136-020-02688-yTest.; Steeves T.D., Day L., Dykeman J., Jette N., Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord. 2012;27(14):1789–1796. https://doi.org/10.1002/mds.25244Test.; Kilic-Berkmen G., Defazio G., Hallett M., Berardelli A., Ferrazzano G., Belvisi D. et al. Diagnosis and classification of blepharospasm: Recommendations based on empirical evidence. J Neurol Sci. 2022;439:120319. https://doi.org/10.1016/j.jns.2022.120319Test.; Duarte G.S., Rodrigues F.B., Marques R.E., Castelão M., Ferreira J., Sampaio C. et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev. 2020;11(11):CD004900. https://doi.org/10.1002/14651858.CD004900.pub3Test.; Scorr L.M., Cho H.J., Kilic-Berkmen G., McKay J.L., Hallett M., Klein C. et al. Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review. Dystonia. 2022;1:10359. https://doi.org/10.3389/dyst.2022.10359Test.; Hwang W.J. Demographic and clinical features of patients with blepharospasm in southern Taiwan: a university hospital- based study. Acta Neurol Taiwan. 2012;21(3):108–114. Available at: http://www.ant-tnsjournal.com/Mag_Files/21-3/002.pdfTest.; Wakakura M., Yamagami A., Iwasa M. Blepharospasm in Japan: A Clinical Observational Study From a Large Referral Hospital in Tokyo. Neuroophthalmology. 2018;42(5):275–283. https://doi.org/10.1080/01658107.2017.1409770Test.; Huang X.F., Wang K.Y., Liang Z.H., Du R.R., Zhou L.N. Clinical Analysis of Patients with Primary Blepharospasm: A Report of 100 Cases in China. Eur Neurol. 2015;73(5-6):337–341. https://doi.org/10.1159/000381707Test.; Peckham E.L., Lopez G., Shamim E.A., Richardson S.P., Sanku S., Malkani R. et al. Clinical features of patients with blepharospasm: a report of 240 patients. Eur J Neurol. 2011;18(3):382–386. https://doi.org/10.1111/j.1468-1331.2010.03161.xTest.; Jinnah H.A. Medical and Surgical Treatments for Dystonia. Neurol Clin. 2020;38(2):325–348. https://doi.org/10.1016/j.ncl.2020.01.003Test.; Simpson D.M., Hallett M., Ashman E.J., Comella C.L., Green M.W., Gronseth G.S. et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818–1826. https://doi.org/10.1212/WNL.0000000000002560Test.; Jankovic J. Botulinum toxin: State of the art. Mov Disord. 2017;32(8):1131–1138. https://doi.org/10.1002/mds.27072Test.; Hassell T.J.W., Charles D. Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins. Toxins (Basel). 2020;12(4):269. https://doi.org/10.3390/toxins12040269Test.; https://www.med-sovet.pro/jour/article/view/7653Test

الإتاحة: https://doi.org/10.21518/ms2023-213Test
https://doi.org/10.1212/con.0000000000000747Test
https://doi.org/10.1093/brain/108.3.593Test
https://doi.org/10.1002/ana.410110108Test
https://doi.org/10.1136/jnnp.51.6.767Test
https://doi.org/10.1007/s00415-012-6510-xTest
https://doi.org/10.1001/jama.1982.03330230060037Test
https://doi.org/10.1034/j.1600-0404.2001.00109.xTest
https://doi.org/10.1136/jnnp.74.3.348Test
https://doi.org/10.1002/mds.25475Test

المؤلفون: R. K. Shikhkerimov, E. V. Istomina, Р. К. Шихкеримов, Е. В. Истомина

المساهمون: This article has been supported by IPSEN Pharma., Статья спонсируется компанией «ИПСЕН».

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 6 (2022); 103-109 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 6 (2022); 103-109 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-6

مصطلحات موضوعية: постинсультная спастичность, botulinum toxin serotypes, recombinant botulinum toxins, botulinum therapy, post-stroke spasticity, серотипы ботулотоксина, рекомбинантные ботулотоксины, ботулинотерапия

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/1928/1484Test; Dressler D. Botulinum toxin drugs: brief history and outlook. J Neural Transm (Vienna). 2016 Mar;123(3):277-9. doi:10.1007/s00702-015-1478-1. Epub 2015 Nov 11.; Jankovic J. Botulinum toxin: State of the art. Mov Disord. 2017 Aug;32(8):1131-8. doi:10.1002/mds.27072. Epub 2017 Jun 22.; Супотницкий МВ. Микроорганизмы, токсины и эпидемии. Москва: Вузовская книга; 2000. Доступно по ссылке: https://www.supotnitskiy.ru/book/book1-1-5.htmTest (дата обращения 10.08.2022).; Chen S. Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments. Toxins. 2012;4(10):913-39. doi:10.3390/toxins4100913; Peck MW, Smith TJ, Anniballi F, et al. Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature. Toxins (Basel). 2017;9(1):38. doi:10.3390/toxins9010038; Masuyer G, Zhang S, Barkho S, et al. Structural characterisation of the catalytic domain of botulinum neurotoxin X-high activity and unique substrate specificity. Sci Rep. 2018 Mar 14;8(1):4518. doi:10.1038/s41598-018-22842-4; Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12(8):535-49. doi:10.1038/nrmicro3295; Орлова ОР. Возможности и перспективы использования ботулотоксина в клинической практике. Русский медицинский журнал. 2006;14(23):3-10. Доступно по ссылке: https://paininfo.ru/articles/rmj/788.htmlTest (дата обращения 10.08.2022).; Mtui EP, Gruener G, Dockery P. Fitzgerald's Clinical Neuroanatomy and Neuroscience. Philadelphia, PA: Elsevier; 2016. P. 85-101.; Dolly JO, Lawrence GW, Meng J, et al. Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr Opin Pharmacol. 2009;9(3):326-35. doi:10.1016/j.coph.2009.03.004; Montecucco C, Papini E, Schiavo G. Bacterial protein toxins penetrate cells via a fourstep mechanism. FEBS Lett. 1994;346(1):92-8. doi:10.1016/0014-5793(94)00449-8; Dressler D. Pharmakologie der Botulinumtoxinmedikamente [Pharmacology of botulinum toxin drugs]. HNO. 2012 Jun;60(6):496-502 (In Germ.). doi:10.1007/s00106-012-2494-1; Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000 Apr;80(2):717-66. doi:10.1152/physrev.2000.80.2.717; Binz T, Rummel A. Cell entry strategy of clostridial neurotoxins. J Neurochem. 2009 Jun;109(6):1584-95. doi:10.1111/j.1471-4159.2009.06093.x. Epub 2009 Apr 28.; Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006 Apr 28;312(5773):592-6. doi:10.1126/science.1123654. Epub 2006 Mar 16.; Pirazzini M, Rossetto O, Eleopra R, et al. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017;69(2):200-35. doi:10.1124/pr.116.012658; Dong M, Richards DA, Goodnough MC, et al. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol. 2003;162(7):1293-303. doi:10.1083/jcb.200305098; Donald S, Elliott M, Gray B, et al. A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo. Pharmacol Res Perspect. 2018;6(6):e00446. doi:10.1002/prp2.446; Tsai YC, Maditz R, Kuo CL, et al. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci USA. 2010;107(38):16554-9. doi:10.1073/pnas.1008302107; Wang J, Zurawski TH, Meng J, et al. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem. 2011;286(8):6375-85. doi:10.1074/jbc.m110.181784; Артеменко АР, Куренков АЛ. Ботулинический токсин: вчера, сегодня, завтра. Нервно-мышечные болезни. 2013;(2):6-19. Доступно по ссылке: https://nmb.abvpress.ru/jour/article/view/44/40Test (дата обращения 10.08.2022).; Fonfria E, Maignel J, Lezmi S, et al. The Expanding Therapeutic Utility of Botulinum Neurotoxins. Toxins (Basel). 2018;10(5):208. doi:10.3390/toxins10050208; Bentivoglio AR, Del Grande A, Petracca M, et al. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015;107(Pt A):77-84. doi:10.1016/j.toxicon.2015.08.001; Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19(10 Suppl):s191-6.; Королев АА. К вопросу о ботулинотерапии постинсультного спастического пареза: механизмы действия ботулотоксина, алгоритм восстановительного лечения. Лечащий врач. 2012;(2):78-84. Доступно по ссылке: https://www.lvrach.ru/2012/02/15435355Test (дата обращения 10.08.2022).; Spasticity in adults: management using botulinum toxin. National guidelines. London: RCP; 2018. Available from: https://www.kcl.ac.uk/cicelysaunders/attachments/spasticity-in-adults-managment-usingbotulinum-toxin.pdfTest; Ишемический инсульт и транзиторная ишемическая атака у взрослых. Клинические рекомендации. Москва: Минздрав России; 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/schema/171_2Test (дата обращения 10.08.2022).; Datta Gupta A, Visvanathan R, Cameron I, et al. Efficacy of botulinum toxin in modifying spasticity to improve walking and quality of life in post-stroke lower limb spasticity – a randomized double-blind placebo controlled study. BMC Neurol. 2019;19(1):96. doi:10.1186/s12883-019-1325-3; Eleopra R, Rinaldo S, Montecucco C, et al. Clinical duration of action of different botulinum toxin types in humans. Toxicon. 2020;179:84-91. doi:10.1016/j.toxicon.2020.02.020; Yoelin SG, Dhawan SS, Vitarella D, et al. Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin, in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled, AscendingDose Study. Plast Reconstr Surg. 2018;142(6):847e-855e. doi:10.1097/PRS.0000000000005029; Webb RP. Engineering of Botulinum Neurotoxins for Biomedical Applications. Toxins (Basel). 2018;10(6):231. doi:10.3390/toxins10060231; Tao L, Peng L, Berntsson RP, et al. Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors. Nat Commun. 2017;8(1):53. doi:10.1038/s41467-017-00064-y; Raphael BH, Choudoir MJ, Luquez C, et al. Sequence diversity of genes encoding botulinum neurotoxin type F. Appl Environ Microbiol. 2010;76(14):4805-12. doi:10.1128/aem.03109-09; Burgin D, Perier C, Hackett G, et al. New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency. Toxins (Basel). 2021;13(12):834. doi:10.3390/toxins13120834; Weisemann J, Krez N, Fiebig U, et al. Generation and Characterization of Six Recombinant Botulinum Neurotoxins as Reference Material to Serve in an International Proficiency Test. Toxins (Basel). 2015;7(12):5035-54. doi:10.3390/toxins7124861; Rasetti-Escargueil C, Popoff MR. Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development. Toxins (Basel). 2020 Dec 22;13(1):1. doi:10.3390/toxins13010001; Fonfria E, Elliott M, Beard M, et al. Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity. Toxins (Basel). 2018 Jul 4;10(7):278. doi:10.3390/toxins10070278; Hooker A, Palan S, Beard M. Recombinant botulinum neurotoxin serotype A1 (SXN102342): Protein engineering and process development. Toxicon. 2016;123:40. doi:10.1016/j.toxicon.2016.11.113; Perier C, Martin V, Cornet S, et al. Recombinant botulinum neurotoxin serotype A1 in vivo characterization. Pharmacol Res Perspect. 2021;9(5):e00857. doi:10.1002/prp2.857; Keith F, John C. Targeted secretion inhibitors-innovative protein therapeutics. Toxins (Basel). 2010 Dec;2(12):2795-815. doi:10.3390/toxins2122795. Epub 2010 Dec 3.; Pons L, Vilain C, Volteau M, et al. Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport®). J Neurol Sci. 2019;407:116516. doi:10.1016/j.jns.2019.116516; Eleopra R, Tugnoli V, Rossetto O, et al. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett. 1998 Nov 13;256(3):135-8. doi:10.1016/s0304-3940(98)00775-7; Jacinto J, Varriale P, Pain E, et al. Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity. Front Neurol. 2020 May 7;11:388. doi:10.3389/fneur.2020.00388. Erratum in: Front Neurol. 2020 Dec 17;11:629181.; A Study to Assess the Safety and Efficacy of IPN10200 of in Adult Participants with Upper Limb Spasticity (LANTIMA). Available from: https://clinicaltrials.govTest; https://nnp.ima-press.net/nnp/article/view/1928Test

الإتاحة: https://doi.org/10.14412/2074-2711-2022-6-103-109Test
https://doi.org/10.14412/2074-2711-2022-6Test
https://doi.org/10.1007/s00702-015-1478-1Test
https://doi.org/10.1002/mds.27072Test
https://doi.org/10.3390/toxins4100913Test
https://doi.org/10.3390/toxins9010038Test
https://doi.org/10.1038/s41598-018-22842-4Test
https://doi.org/10.1038/nrmicro3295Test
https://doi.org/10.1016/j.coph.2009.03.004Test
https://doi.org/10.1016/0014-5793Test(94)00449-8

المؤلفون: A. L. Kurenkov, L. M. Kuzenkova, B. I. Bursagova, V. V. Chernikov, O. V. Agranovich, L. G. Khachatryan, V. M. Kenis, V. A. Zherebtsova, M. N. Sarzhina, N. D. Odinaeva, A. R. Artemenko, G. A. Popova, E. A. Moroshek, E. E. Tabe, A. A. Nezhelskaya, A. A. Maksimenko, L. Ya. Akhadova, M. V. Indereikin, N. V. Duibanova, L. V. Tikhonova, A. V. Sapogovskiy, Z. M. Gadzhialieva, A. V. Grigorieva, V. S. Perminov, I. D. Fedonyuk, L. M. Kolpakchi, A. Yu. Kursakova, N. A. Tsurina, А. Л. Куренков, Л. М. Кузенкова, Б. И. Бурсагова, В. В. Черников, О. В. Агранович, Л. Г. Хачатрян, В. М. Кенис, В. А. Жеребцова, М. Н. Саржина, Н. Д. Одинаева, А. Р. Артеменко, Г. А. Попова, Е. А. Морошек, Е. Э. Табе, А. А. Нежельская, А. А. Максименко, Л. Я. Ахадова, М. В. Индерейкин, Н. В. Дуйбанова, Л. В. Тихонова, А. В. Сапоговский, З. М. Гаджиалиева, А. В. Григорьева, В. С. Перминов, И. Д. Федонюк, Л. М. Колпакчи, А. Ю. Курсакова, Н. А. Цурина

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 2 (2022); 117-125 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 2 (2022); 117-125 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-2

مصطلحات موضوعية: общая доза, botulinum therapy, incobotulinumtoxinA, lower limbs spasticity, upper limbs spasticity, sialorrhea, total dose, ботулинотерапия, спастичность нижних конечностей, спастичность верхних конечностей, сиалорея

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/1795/1401Test; https://nnp.ima-press.net/nnp/article/view/1795/1404Test; Sadowska M, Sarecka-Hujar B, Kopyta I. Cerebral palsy: current opinions on definition, epidemiology, risk factors, classification and treatment options. Neuropsychiatr Dis Treat. 2020 Jun 12;16:1505-1518. doi:10.2147/NDT.S235165; Graham HK, Rosenbaum P, Paneth N, et al. Cerebralpalsy. Nat Rev Dis Primers. 2016 Jan 7;2:15082. doi:10.1038/nrdp.2015.82; Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010 Jan;14(1):45-66. doi:10.1016/j.ejpn.2009.09.005. Epub 2009 Nov 14.; Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep. 2020 Feb 21;20(2):3. doi:10.1007/s11910-020-1022-z; Delgado MR, Bonikowski M, Carranza J, et al. Safety and efficacy of repeat open-label abobotulinumtoxinA treatment in pediatric cerebral palsy. J Child Neurol. 2017 Nov;32(13):1058-64. doi:10.1177/0883073817729918. Epub 2017 Sep 15.; Heinen F, Kanovsky P, Schroeder AS, et al. IncobotulinumtoxinA for the treatment of lowerlimb spasticity in children and adolescents with cerebral palsy: A phase 3 study. J Pediatr Rehabil Med. 2021;14(2):183-97. doi:10.3233/PRM-210040; Kanovsky P, Heinen F, Schroeder AS, et al. Safety and efficacy of repeat long-term incobotulinumtoxinA treatment for lower limb or combined upper/lower limb spasticity in children with cerebralpalsy. J Pediatr Rehabil Med. 2021 Dec; Куренков АЛ, Клочкова ОА, Кузенкова ЛМ и др. Многоуровневая ботулинотерапия при спастических формах детского церебрального паралича с тяжелыми двигательными нарушениями (GMFCS IV–V). Журнал неврологии и пси- хиатрии им. С.С. Корсакова. 2020;120(12):57-66. doi:10.17116/jnevro202012012157; Molenaers G, Desloovere K, Fabry G, De Cock P. The effects of quantitative gait assessment and botulinum toxin a on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am. 2006 Jan;88(1):161-70. doi:10.2106/JBJS.C.01497; Кенис ВМ. Ортопедическое лечение деформаций стоп у детей с церебральным параличом: Автореф. дисс. … докт. мед. наук. Санкт-Петербург; 2014. 45 с.; Змановская ВА, Левитина ЕВ, Попков ДА и др. Длительное применение препарата ботулинического токсина типа А: Диспорт в комплексной реабилитации детей со спастическими формами церебрального паралича. Журнал неврологии и психиатрии им. С.С. Корса- кова. 2014;114(7):33-6.; Rowe FJ, Noonan CP. Botulinum toxin for the treatment of strabismus. Cochrane Database Syst Rev. 2017 Mar 2;3(3):CD006499. doi:10.1002/14651858.CD006499.pub4; Berweck S, Bonikowski M, Kim H, et al. Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children: SIPEXI. Neurology. 2021 Aug 2;97(14):e1425-e1436. doi:10.1212/WNL.0000000000012573. Online ahead of print.; Jost WH, Steffen A, Berweck S. A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients. Expert Rev Neurother. 2021 Oct;21(10):1059-68. doi:10.1080/14737175.2021.1979959. Epub 2021 Oct 4.; Love SC, Novak I, Kentish M, et al.; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010 Aug;17 Suppl 2:9-37. doi:10.1111/j.1468-1331.2010.03126.x; Spasticity in children and young people with non-progressive brain disorders. London: Published by the RCOG Press at the Royal College of Obstetricians and Gynaecologists; 2012. 298 p.; Куренков АЛ, Клочкова ОА, Бурсагова БИ и др. Эффективность и безопасность применения ботулинического токсина типа А при лечении детского церебрального паралича. Журнал неврологии и психиатрии. 2017;117(11):44-51.; Carraro E, Trevisi E, Martinuzzi A. Safety profile of incobotulinum toxin A [Xeomin®] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial. Eur J Paediatr Neurol. 2016;20(4):532-7.; Leon-Valenzuela A, Palacios JS, Del Pino Algarrada R. IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy – a retrospective case series focusing on dosing and tolerability. BMC Neurol. 2020 Apr 8;20(1):126. doi:10.1186/s12883-020-01702-7; Dabrowski E, Chambers HG, Gaebler-Spira D, et al. IncobotulinumtoxinA efficacy/safety in upper-limb spasticity in pediatric cerebral palsy: randomized controlled trial. Pediatr Neurol. 2021 Oct;123:10-20. doi:10.1016/j.pediatrneurol. 2021.05.014. Epub 2021 May 21.; Куренков АЛ, Кузенкова ЛМ, Черников ВВ и др. Применение IncobotulinumtoxinA для лечения сиалореи у пациентов с детским церебральным параличом. Неврология, нейропсихиатрия, психосоматика. 2021;13(4):52-9. doi:10.14412/2074- 2711-2021-4-52-59; Куренков АЛ, Агранович ОВ, Кузенкова ЛМ и др. Выбор дозы препарата IncobotulinumtoxinA для лечения спастичности и сиалореи при детском церебральном параличе: результаты ретроспективного многоцентрового исследования. Неврологический журнал им. Л.О. Бадаляна. 2021;2(4):189-202. doi:10.46563/2686-8997-2021-2-4-189-202; Almina S, Karile Y, Audrone P, Indre B. Analgesic effect of botulinum toxin in children with cerebral palsy: A systematic review. Toxicon. 2021 Aug;199:60-67. doi:10.1016/j.toxicon.2021.05.012. Epub 2021 Jun 1.; Хачатрян ЛГ, Лялина АА, Зотова НС и др. Эффективность применения препарата ботулинического токсина типа А в лечении мышечной дистонии у детей. Вопросы практической педиатрии. 2019;14(3):58-67. doi:10.20953/1817-7646-2019-3-58-67; https://nnp.ima-press.net/nnp/article/view/1795Test

الإتاحة: https://doi.org/10.14412/2074-2711-2022-2-117-125Test
https://doi.org/10.14412/2074-2711-2022-2Test
https://doi.org/10.2147/NDT.S235165Test
https://doi.org/10.1038/nrdp.2015.82Test
https://doi.org/10.1016/j.ejpn.2009.09.005Test
https://doi.org/10.1007/s11910-020-1022-zTest
https://doi.org/10.1177/0883073817729918Test
https://doi.org/10.3233/PRM-210040Test
https://doi.org/10.3233/PRM-210041Test
https://doi.org/10.17116/jnevro202012012157Test

المؤلفون: S. A. Malmberg

المصدر: Русский журнал детской неврологии, Vol 15, Iss 1, Pp 8-17 (2020)

مصطلحات موضوعية: идиопатическая ходьба на пальцах стоп у детей, дифференциальный диагноз, лечение, ботулинотерапия, контрактуры в голеностопных суставах, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: https://rjdn.abvpress.ru/jour/article/view/319Test; https://doaj.org/toc/2073-8803Test; https://doaj.org/toc/2412-9178Test

الوصول الحر: https://doaj.org/article/2af5a865a15e4547b17c90d127817b81Test

المؤلفون: O. R. Orlova, M. I. Soykher, M. G. Soykher, L. R. Mingazova, D. V. Medovnikova, E. M. Soykher, Z. N. Konovalova, A. Yu. Alekseeva

المصدر: Нервно-мышечные болезни, Vol 9, Iss 2, Pp 12-20 (2019)

مصطلحات موضوعية: бруксизм, жевательные мышцы, боль, ботулинический нейропротеин, ботулинотерапия, брукс-чекеры, электромиография, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: https://nmb.abvpress.ru/jour/article/view/322Test; https://doaj.org/toc/2222-8721Test; https://doaj.org/toc/2413-0443Test

الوصول الحر: https://doaj.org/article/000372a20f074b79b1dd02d132819a48Test

المؤلفون: O. A. Druzhinina, L. P. Shperling, N. G. Zhukova

المصدر: Сибирский научный медицинский журнал, Vol 38, Iss 3, Pp 71-79 (2019)

مصطلحات موضوعية: цервикальная дистония, эпидемиология, мультифакториальность, классификация, ботулинотерапия, Medicine

وصف الملف: electronic resource

العلاقة: https://sibmed.elpub.ru/jour/article/view/39Test; https://doaj.org/toc/2410-2512Test; https://doaj.org/toc/2410-2520Test

الوصول الحر: https://doaj.org/article/c064738e3d6943e7962b64b6e5eb96beTest

المؤلفون: A. Kurenkov L., L. Kuzenkova M., V. Chernikov V., B. Bursagova I., A. Nezhelskaya A., A. Artemenko R., А. Куренков Л., Л. Кузенкова М., В. Черников В., Б. Бурсагова И., А. Нежельская А., А. Артеменко Р.

المساهمون: This article has been supported by Merz., Статья спонсируется компанией Merz.

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 4 (2021); 52-59 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 4 (2021); 52-59 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-4

مصطلحات موضوعية: infantile cerebral palsy, sialorrhea, salivation, IncobotulinumtoxinA, botulinum therapy, Drooling Impact Scale, Global Impression of Change Scale, детский церебральный паралич, сиалорея, слюнотечение, ботулинотерапия, Шкала оценки влияния слюнотечения, Шкала изменения общего впечатления

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/1628/1280Test; Graham HK, Rosenbaum P, Paneth N, et al. Cerebral palsy. Nat Rev Dis Primers. 2016 Jan 7;2:15082. doi:10.1038/nrdp.2015.82; Himmelmann K, Panteliadis CP. Clinical Characteristics. In: Panteliadis CP, ed. Cerebral palsy: A Multidisciplinary Approach. 3rd ed. Cham: Springer, 2018. P. 75-87.; Intagliata V, Stevenson R. Feeding and nutrition. In: Dan B, Mayston M, Paneth N, Rosenbloom L, eds. Cerebral palsy: science and clinical practice. London: Mac Keith Press; 2014. P. 601-16.; Lakraj AA, Moghimi N, Jabbari B. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013 May 21;5(5):1010-31. doi:10.3390/toxins5051010; Dias BL, Fernandes AR, Maia Filho HS. Sialorrhea in children with cerebral palsy. J Pediatr (Rio J). 2016;92(6):549-58. doi:10.1016/j.jped.2016.03.006; Erasmus CE, van Hulst K, Rotteveel JJ, et al. Clinical practice: swallowing problems in cerebral palsy. Eur J Pediatr. 2012;171(3):409-14. doi:10.1007/s00431-011-1570-y; Fairhurst CB, Cockerill H. Management of drooling in children. Arch Dis Child Educ Pract Ed. 2011 Feb;96(1):25-30. doi:10.1136/adc.2007.129478. Epub 2010 Jul 30.; Johnson H, Scott A. Saliva Management. In: Cichero JAY, Murdoch BE, eds. Dysphagia: Foundation, Theory and Practice. Chichester -New York- Weinheim - Brisbane - Toronto -Singapore: John Wiley & Sons Ltd; 2006. P. 126-9.; Erasmus CE, van Hulst K, Rotteveel LJ, et al. Drooling in cerebral palsy: hypersalivation or dysfunctional oral motor control? Dev Med Child Neurol. 2009 Jun;51(6):454-9. doi:10.1111/j.1469-8749.2008.03243.x. Epub 2009 Feb 3.; Novak I, Morgan C, Fahey M, et al. State of the evidence traffic lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Curr Neurol Neurosci Rep. 2020 Feb 21;20(2):3. doi:10.1007/s11910-020-1022-z; Jongerius PH, Rotteveel JJ, van den Hoogen F, et al. Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. Eur J Pediatr. 2001 Aug;160(8):509-12. doi:10.1007/s004310100784; Reddihough D, Erasmus CE, Johnson H, et al; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. Eur J Neurol. 2010 Aug;17 Suppl 2:109-21. doi:10.1111/j.1468-1331.2010.03131.x; Rodwell K, Edwards P, Ware RS, Boyd R. Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelopmental disability: a systematic review. Dev Med Child Neurol. 2012 Nov;54(11):977-87. doi:10.1111/j.1469-8749.2012.04370.x. Epub 2012 Sep 5.; Носко АС, Зыков ВП, Комарова ИБ. Коррекция сиалореи в нейропедиатрии. Фокус на препаратах ботулинического токсина типа Акак метод первого ряда выбора. Детская и подростковая реабилитация. 2013;21(2):33-8.; Naumann M, Dressler D, Hallett M, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013;67:141-52. doi:10.1016/j.toxicon.2012.10.020; Lungren MP, Halula S, Coyne S, et al. Ultrasound-guided botulinum toxin type A salivary gland injection in children for refractory sialorrhea: 10-year experience at a large tertiary children's hospital. Pediatr Neurol. 2016 Jan;54:70-5. doi:10.1016/j.pediatrneurol.2015.09.014. Epub 2015 Sep 28.; Van Hulst K, van Der Burg JJ, Jongerius PH, et al. Changes in severity and impact of drooling after submandibular gland botulinum neurotoxin A injections in children with neurodevelopmental disabilities. Dev Med Child Neurol. 2020 Mar;62(3):354-62. doi:10.1111/dmcn.14391. Epub 2019 Nov 14.; Berweck S, Kim H, Banach M, et al; on behalf of the SIPEXI Study Group. Efficacy of Incobotulinumtoxin/A in the treatment of 6- to 17-year-old children and adolescents with chronic sialorrhea associated with neurological disorders and/or intellectual disability. Toxicon. 2020;190:S7-S8.; Reid SM, Johnson HM, Reddihough DS. The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities. Dev Med Child Neurol. 2010 Feb;52(2):e23-8. doi:10.1111/j.1469-8749.2009.03519.x. Epub 2009 Oct 15.; Jost WH, Friedman A, Michel O, et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019 Apr 23;92(17):e1982-e1991. doi:10.1212/WNL.0000000000007368. Epub 2019 Mar 27.; Berweck S, Bonikowski M, Banach M, et al; on behalf of the SIPEXI Study Group. Efficacy and safety of Incobotulinumtoxin/A in the treatment of 2- to 5-year-old children with chronic sialorrhea associated with neurological disorders and/or intellectual disability. Toxicon. 2020;190:S8-S9.; Savarese R, Diamond M, Elovic E, Millis SR. Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil. 2004 Apr;83(4):304-11; quiz 312-4, 336. doi:10.1097/01.phm.0000104680.28335.b9; Alrefai AH, Aburahma SK, Khader YS. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial. Clin Neurol Neurosurg. 2009 Jan;111(1):79-82. doi:10.1016/j.clineuro.2008.09.001. Epub 2008 Nov 1.; Jongerius PH, van den Hoogen FJ, van Limbeek J, et al. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics. 2004 Sep;114(3):620-7. doi:10.1542/peds.2003-1104-L; Erasmus CE, Scheffer AR, van Hulst K, et al. Does motor performance matter in botulinum toxin efficacy for drooling? Pediatr Neurol. 2011;45(2):95-9. doi:10.1016/j.pediatrneurol.2011.02.011; Banerjee KJ, Glasson C, O'Flaherty SJ. Parotid and submandibular botulinum toxin A injections for sialorrhea in children with cerebral palsy. Dev Med Child Neurol. 2006 Nov;48(11):883-7. doi:10.1017/S0012162206001939; Reid SM, Johnstone BR, Westbury C, et al. Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Dev Med Child Neurol. 2008 Feb;50(2):123-8. doi:10.1111/j.1469-8749.2007.02010.x; Surmelioglu О, Dagkiran M, Tuncer U, et al. The effectiveness of botulinum toxin type A injections in the management of sialorrhea. Turk Arch Otorhinolaryngol. 2018;56(2):111-3. doi:10.5152/tao.2018.2411; Tiigimae-Saar J, Leibur E, Kolk A, et al. Use of botulinum neurotoxin A in uncontrolled salivation in children with cerebral palsy: a pilot study. Int J Oral Maxillofac Surg. 2012;41(12):1540-5. doi:10.1016/j.ijom.2012.09.015; Клочкова ОА, Куренков АЛ, Каримова ХМ и др. Сиалоррея у пациентов с детским церебральным параличом: эффективность применения ботулинотерапии. Педиатрическая фармакология. 2015;12(4):398-406.; Isaacson SH, Ondo W, Jackson CE, et al; MYSTICOL Study Group. Safety and efficacy of rimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial. JAMA Neurol. 2020 Apr 1;77(4):461-9. doi:10.1001/jamaneurol.2019.4565; Sales HF, Cerqueira C, Vaz D, et al. The impact of botulinum toxin type A in the treatment of drooling in children with cerebral palsy secondary to Congenital Zika Syndrome: an observational study. Neurol Res. 2021 Jan;43(1):54-60. doi:10.1080/01616412.2020.1820698. Epub 2020 Sep 11.; Berweck S, Bonikowski M, Kim H, et al; on behalf of the SIPEXI Study Group. Safety of Incobotulinumtoxin/A in the treatment of 6-to 17-year-old children and adolescents with chronic sialorrhea associated with neurological disorders and/or intellectual disability. Toxicon. 2020;190:S8.; https://nnp.ima-press.net/nnp/article/view/1628Test

الإتاحة: https://doi.org/10.14412/20742711-2021-4-52-59Test
https://doi.org/10.14412/2074-2711-2021-4Test
https://doi.org/10.1038/nrdp.2015.82Test
https://doi.org/10.3390/toxins5051010Test
https://doi.org/10.1016/j.jped.2016.03.006Test
https://doi.org/10.1007/s00431-011-1570-yTest
https://doi.org/10.1136/adc.2007.129478Test
https://doi.org/10.1007/s11910-020-1022-zTest
https://doi.org/10.1007/s004310100784Test
https://doi.org/10.1111/j.1468-1331.2010.03131.xTest

المؤلفون: O. V. Bugun, A. V. Mashanskaya, A. V. Atalyan, V. I. Mikhnovich, T. A. Belogorova, A. V. Vlasenko, V. R. Minulin, Zh. V. Prokhorova, О. В. Бугун, А. В. Машанская, А. В. Аталян, В. И. Михнович, Т. А. Белогорова, А. В. Власенко, В. Р. Минулин, Ж. В. Прохорова

المساهمون: Работа выполнена в рамках госзадания ФГБНУ НЦ ПЗСРЧ.Выражение признательности Авторы статьи выражают признательность О.М. Литвинцевой за участие в разработке комплекса лечебной физкультуры и подборе физических упражнений, а также за помощь в проведении анализа и интерпретации результатов GMFM.

المصدر: Acta Biomedica Scientifica; Том 6, № 6-2 (2021); 82-91 ; 2587-9596 ; 2541-9420

مصطلحات موضوعية: аппараты с биологической обратной связью, rehabilitation, botulinum therapy, physical exercises, biofeedback devices, реабилитация, ботулинотерапия, физические упражнения

وصف الملف: application/pdf

العلاقة: https://www.actabiomedica.ru/jour/article/view/3145/2284Test; Graham HK, Rosenbaum P, Paneth N, Dan B, Lin JP, Damiano DL, et al. Cerebral palsy. Nat Rev Dis Primers. 2016; 2: 15082.; Prosser LA, Pierce SR, Dillingham TR, Bernbaum JC, Jawad AF. iMOVE: Intensive Mobility training with Variability and Error compared to conventional rehabilitation for young children with cerebral palsy: the protocol for a single blind randomized controlled trial. BMC Pediatr. 2018; 18(1): 329. doi:10.1186/s12887-018-1303-8; Vitrikas K, Dalton H, Breish D. Cerebral palsy: An overview. Am Fam Physician. 2020; 101(4): 213-220.; Michael-Asalu A, Taylor G, Campbell H, Lelea LL, Kirby RS. Cerebral palsy: Diagnosis, epidemiology, genetics, and clinical update. Adv Pediatr. 2019; 66: 189-208. doi:10.1016/j.yapd.2019.04.002; Баранов А.А., Альбицкий В.Ю., Намазова-Баранова Л.С., Терлецкая Р.Н. Состояние здоровья детей в современной России; 2-е изд., доп. М.: ООО Изд-во «Педиатръ»; 2020.; Мыльникова И.В., Кузьмина М.В, Туров В.М. Комплексная оценка потерь здоровья детского и подросткового населения Иркутской области. Гигиена и санитария. 2019; 98(10): 1135-1140. doi:10.18821/0016-9900-2019-98-10-1135-1140; Зелинская Д.И., Терлецкая Р.Н. Инвалидность детского населения России (современные правовые и медико-социальные процессы). М.: Изд-во «Юрайт»; 2019.; Кондакова Н.А., Нацун Л.Н. Инвалидность детского населения как медико-социальная проблема.Здоровье человека, теория и методика физической культуры и спорта. 2019; 4(15): 285-296.; Novak I, Morgan C, Fahey M, Finch-Edmondson M, Galea C, Hines A, et al. State of the Evidence Traffic Lights 2019: Systematic review of interventions for preventing and treating children with cerebral palsy. Curr Neurol Neurosci Rep. 2020; 20(2): 3. doi:10.1007/s11910-020-1022-z; Graham D, Paget SP, Wimalasundera N. Current thinking in the health care management of children with cerebral palsy. Med J Aust. 2019; 210(3): 129-135. doi:10.5694/mja2.12106; Бердина О., Михнович В., Белогорова Т., Власенко А., Большакова С., Бугун О., и др. Реабилитация детей со спастическими формами ДЦП (новые технологии). Врач. 2019; 30(9): 52-56. doi:10.29296/25877305-2019-09-10; Nicolini-Panisson RD, Tedesco AP, Folle MR, Donadio MVF. Selective dorsal rhizotomy in cerebral palsy: Selection criteria and postoperative physical therapy protocols. Rev Paul Pediatr. 2018; 36(1): 9. doi:10.1590/1984-0462/;2018;36;1;00005; Галкина Л.С. Особенности применения физических упражнений у детей с двигательными нарушениями и нарушением функции опоры. Детская и подростковая реабилитация. 2019; 4(40): 21.; Blumetti FC, Belloti JC, Tamaoki MJ, Pinto JA. Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy. Cochrane Database Syst Rev. 2019; 10(10): CD001408. doi:10.1002/14651858.CD001408.pub2; Клочкова О.А., Куренков А.Л. Выбор целей и приоритетов ботулинотерапии у пациентов с детским церебральным параличом. Журнал неврологии и психиатрии им. C.C. Корсакова. 2019; 119(2): 118-124. doi: 0.17116/jnevro2019119021118; Османов Э.А., Ларина Н.В., Власенко С.В., Голубова Т.Ф., Марусич И.И., Кушнир Г.М. Особенности санаторно-курортной реабилитации тяжёлых форм спастических двигательных расстройств у больных детским церебральным параличом. Журнал неврологии и психиатрии им. C.C. Корсакова. 2019; 119(6): 47-52. doi:10.17116/jnevro201911906147; Власенко С.В., Голубова Т.Ф., Марусич И.И., Ларина Н.В., Пономаренко Е.Н. Комплексная санаторно-курортная реабилитация больных ДЦП со спастической диплегией. Журнал неврологии и психиатрии им. C.C. Корсакова. 2018; 118(7): 40-44. doi:10.17116/jnevro20181187140; Chiu HC, Ada L. Constraint-induced movement therapy improves upper limb activity and participation in hemiplegic cerebral palsy: A systematic review. J Physiother. 2016; 62(3): 130-137. doi:10.1016/j.jphys.2016.05.013; Ryan JM, Cassidy EE, Noorduyn SG, O’Connell NE. Exercise interventions for cerebral palsy. Cochrane Database Syst Rev. 2017; 6(6): CD011660. doi:10.1002/14651858.CD011660.pub2; Дейнеко В.В., Крысюк О.Б., Сафонов Л.В., Шурыгин С.Н. Современные возможности и прогноз физической реабилитации детей с церебральным параличом. Журнал неврологии и психиатрии им. C.C. Корсакова. 2020; 120(6): 88-91. doi:10.17116/jnevro202012006188; Куренков А.Л., Клочкова О.А., Змановская В.А., Фальковский И.В., Кенис В.М., Владыкина Л.Н., и др. Первый российский консенсус по применению многоуровневых инъекций abobotulinumtoxin A при лечении спастических форм детского церебрального паралича. Журнал неврологии и психиатрии им. C.C. Корсакова. 2016; 116(11): 121-130. doi:10.17116/jnevro2016116111121-130; Змановская В.А., Левитина Е.В., Кашуба Е.В., Рудзевич И.Л., Бунькова С.А. Комплексная реабилитация детей с детским церебральным параличом. Университетская медицина Урала. 2018; 4(15): 8-10.; Бийкузиева А.А., Шарипов У.А. Комплекс лечебной физкультуры и кинезиотерапии в реабилитации детей с детским церебральным параличом. Развитие и актуальные вопросы современной науки. 2019; 3(22): 41-43.; Koca K, Yıldız C, Yurttaş Y, Balaban B, Hazneci B, Bilgiç S, et al. Serebral palsili çocuklarda çok seviyeli ortopedik cerrahi tedavinin sonuçları [Outcomes of multilevel orthopedic surgery in children with cerebral palsy]. Eklem Hastalik Cerrahisi. 2011; 22(2): 69-74. (In Turkish).; Куренков А.Л., Фисенко Д.А., Кузенкова Л.М., Черников В.В., Литвак Ф.Г., Ашрафова У.Ш., и др. Эффективность сочетанного применения ботулинотерапии и функциональной электрической стимуляции у амбулаторных пациентов со спастическими формами детского церебрального паралича. Неврологический журнал им. Л.О. Бадаляна. 2020; 1(2): 80-90. doi:10.17816/2686-8997-2020-1-2-80-90; Ryan JM, Lavelle G, Theis N, Noorkoiv M, Kilbride C, Korff T, et al. Progressive resistance training for adolescents with cerebral palsy: The STAR randomized controlled trial. Dev Med Child Neurol. 2020; 62(11): 1283-1293. doi:10.1111/dmcn.14601; van Vulpen LF, de Groot S, Rameckers E, Becher JG, Dallmeijer AJ. Improved walking capacity and muscle strength after functional power-training in young children with cerebral palsy. Neurorehabil Neural Repair. 2017; 31(9): 827-841. doi:10.1177/1545968317723750; Almeida KM, Fonseca ST, Figueiredo PRP, Aquino AA, Mancini MC. Effects of interventions with therapeutic suits (clothing) on impairments and functional limitations of children with cerebral palsy: A systematic review. Braz J Phys Ther. 2017; 21(5): 307-320. doi:10.1016/j.bjpt.2017.06.009; Saquetto M, Carvalho V, Silva C, Conceição C, GomesNeto M. The effects of whole body vibration on mobility and balance in children with cerebral palsy: A systematic review with meta-analysis. J Musculoskelet Neuronal Interact. 2015; 15(2): 137-144.; Muñoz-Blanco E, Merino-Andrés J, Aguilar-Soto B, García YC, Puente-Villalba M, Pérez-Corrales J, et al. Influence of aquatic therapy in children and youth with cerebral palsy: A qualitative case study in a special education school. Int J Environ Res Public Health. 2020; 17(10): 3690. doi:10.3390/ijerph17103690; Mendizábal Alonso P. Intervenciones fisioterápicas mediante hipoterapia en el tratamiento de la parálisis cerebral infantil. Revisión bibliográfica [Physiotherapy interventions through hippotherapy in the treatment of cerebral palsy. A literature review]. Rehabilitacion (Madr). 2020; 54(2): 96-106. (In Spanish). doi:10.1016/j.rh.2019.11.003; Федорова И.Н., Чуриков Е.Д. Адаптивная верховая езда как средство реабилитации детей 7–14 лет со спастической формой детского церебрального паралича. Современные вопросы биомедицины. 2019; 3(1-6): 55-62.; Berdina ON, Bairova TA, Rychkova LV, Sheptunov SA. The pediatric robotic-assisted rehabilitation complex for children and adolescents with cerebral palsy: Background and product design. Quality Management, Transport and Information Security, Information Technologies (IT and QM and IS 2017): Proceedings of the International Conference. St. Petersburg; 2017: 360-363. doi:10.1109/ITMQIS.2017.8085834; Lobato Garcia L, González González Y, Da Cuña Carrera I, Alonso Calvete A. Beneficios de la robótica en la rehabilitación de la marcha en la parálisis cerebral: una revisión sistemática [Benefits of robotics in gait rehabilitation in cerebral palsy: A systematic review]. Rehabilitacion (Madr). 2020; 54(2): 128-136. (In Spanish). doi:10.1016/j.rh.2020.01.004; Бердина О.Н., Михнович В.И., Белогорова Т.А., Власенко А.В., Большакова С.Е., Бугун О.В., и др. Эффективные возможности применения роботизированной биомеханотерапии в реабилитации пациентов с детским церебральным параличом. Фарматека. 2018; S5: 54-57.; Sorsdahl AB, Moe-Nilssen R, Kaale HK, Rieber J, Strand LI. Change in basic motor abilities, quality of movement and everyday activities following intensive, goal-directed, activity-focused physiotherapy in a group setting for children with cerebral palsy. BMC Pediatr. 2010; 10: 26. doi:10.1186/1471-2431-10-26; Gimigliano F. Are exercise interventions effective in patients with cerebral palsy? A Cochrane Review summary with commentary. Dev Med Child Neurol. 2020; 62(1): 18-20. doi:10.1111/dmcn.14400; Butler E, Greve K. Commentary on “Stretching and progressive resistance exercise in children with cerebral palsy: A randomized controlled trial”. Pediatr Phys Ther. 2019; 31(3): 271. doi:10.1097/PEP.0000000000000623; Alotaibi M, Long T, Kennedy E, Bavishi S. The efficacy of GMFM-88 and GMFM-66 to detect changes in gross motor function in children with cerebral palsy (CP): A literature review. Disabil Rehabil. 2014; 36(8): 617-627. doi:10.3109/09638288.2013.805820; Liang X, Tan Z, Yun G, Cao J, Wang J, Liu Q, et al. Effectiveness of exercise interventions for children with cerebral palsy: A systematic review and meta-analysis of randomized controlled trials. J Rehabil Med. 2021; 53(4): jrm00176. doi:10.2340/16501977-2772; https://www.actabiomedica.ru/jour/article/view/3145Test

الإتاحة: https://doi.org/10.29413/ABS.2021-6.6-2.9Test
https://doi.org/10.1038/nrdp.2015.82Test
https://doi.org/10.1186/s12887-018-1303-8Test
https://doi.org/10.1016/j.yapd.2019.04.002Test
https://doi.org/10.18821/0016-9900-2019-98-10-1135-1140Test
https://doi.org/10.1007/s11910-020-1022-zTest
https://doi.org/10.5694/mja2.12106Test
https://doi.org/10.29296/25877305-2019-09-10Test
https://doi.org/10.1590/1984-0462/;2018;36;1;00005Test
https://doi.org/10.1002/14651858.CD001408.pub2Test